TGFB1 and breast carcinoma: All biochemical markers were significantly increased in patients with breast cancer with bone metastases, when compared to either the patients with breast cancer without bone metastases or healthy controls, except for TGFβ1 levels, which were significantly decreased (P=0.05 and P=0.005, respectively) (Figures 1, 2 and 3).